OAM
GALT icon

Oxford Asset Management’s Galectin Therapeutics GALT Stock Holding History

Oxford Asset Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-27,906
Closed -$80K – 628
2019
Q4 		$80K Buy
+27,906
New +$97K ﹤0.01% 1636
2019
Q1 		– Sell
-42,236
Closed -$145K – 1766
2018
Q4 		$145K Buy
+42,236
New +$202K ﹤0.01% 1601
2018
Q1 		– Sell
-45,761
Closed -$161K – 1711
2017
Q4 		$161K Buy
+45,761
New +$116K ﹤0.01% 1482

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Oxford Asset Management's GALT Position: Q1 2020 in Review

Oxford Asset Management sold out of Galectin Therapeutics (GALT) in Q1 2020, closing a stake of 27,906 shares — an estimated $80K sold.

Oxford Asset Management first reported a position in GALT in Q4 2017 and held it in 3 quarters. The position peaked at $161K in Q4 2017. 77 funds tracked by Wall St. Rank hold GALT as of Q1 2020.

  • Oxford Asset Management reported no remaining Galectin Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 27,906 Galectin Therapeutics shares in Q1 2020, an estimated $80K.
  • Oxford Asset Management first reported a position in Galectin Therapeutics in Q4 2017 and held it in 3 quarters.
  • Oxford Asset Management's Galectin Therapeutics position peaked at $161K in Q4 2017.
  • 77 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.